266 related articles for article (PubMed ID: 24512487)
21. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
22. Lipid droplet accumulation and adipophilin expression in follicular thyroid carcinoma.
Hayakawa M; Taylor JN; Nakao R; Mochizuki K; Sawai Y; Hashimoto K; Tabata K; Kumamoto Y; Fujita K; Konishi E; Hirano S; Tanaka H; Komatsuzaki T; Harada Y
Biochem Biophys Res Commun; 2023 Jan; 640():192-201. PubMed ID: 36521425
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
Hoelting T; Siperstein AE; Clark OH; Duh QY
J Clin Endocrinol Metab; 1994 Aug; 79(2):401-8. PubMed ID: 8045955
[TBL] [Abstract][Full Text] [Related]
24. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer.
Sandrini F; Matyakhina L; Sarlis NJ; Kirschner LS; Farmakidis C; Gimm O; Stratakis CA
Genes Chromosomes Cancer; 2002 Oct; 35(2):182-92. PubMed ID: 12203783
[TBL] [Abstract][Full Text] [Related]
25. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
[TBL] [Abstract][Full Text] [Related]
26.
Pitsava G; Stratakis CA; Faucz FR
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359735
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.
Witte J; Lehmann S; Wulfert M; Yang Q; Röher HD
World J Surg; 2007 Jan; 31(1):51-9. PubMed ID: 17171498
[TBL] [Abstract][Full Text] [Related]
28. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
[TBL] [Abstract][Full Text] [Related]
29. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
[TBL] [Abstract][Full Text] [Related]
30. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
31. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
[TBL] [Abstract][Full Text] [Related]
33. Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.
Ashtekar A; Huk D; Magner A; La Perle KMD; Boucai L; Kirschner LS
J Clin Endocrinol Metab; 2018 Nov; 103(11):4135-4145. PubMed ID: 30165401
[TBL] [Abstract][Full Text] [Related]
34. G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine.
Suteau V; Seegers V; Munier M; Ben Boubaker R; Reyes C; Gentien D; Wery M; Croué A; Illouz F; Hamy A; Rodien P; Briet C
J Clin Endocrinol Metab; 2021 Jul; 106(8):2221-2232. PubMed ID: 34000025
[TBL] [Abstract][Full Text] [Related]
35. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
36. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
37. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
38. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.
Burrows N; Resch J; Cowen RL; von Wasielewski R; Hoang-Vu C; West CM; Williams KJ; Brabant G
Endocr Relat Cancer; 2010 Mar; 17(1):61-72. PubMed ID: 19808899
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium.
Yeager N; Brewer C; Cai KQ; Xu XX; Di Cristofano A
Cancer Res; 2008 Jan; 68(2):444-9. PubMed ID: 18199538
[TBL] [Abstract][Full Text] [Related]
40. ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma.
Miao X; Zhao Y
Oncol Rep; 2016 Apr; 35(4):2131-40. PubMed ID: 26820593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
